Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE: Granulocyte-augmented Cord Blood Transplantation for Young Adults With Very Poor Risk AML
NCT07372885Phase 2Not yet recruiting
- Sponsor
- The University of Manchester
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of granulocytes in acute myeloid leukemia (AML) (5 arms), sponsored by The University of Manchester. Primary endpoints: Cytokine Release Syndrome at Day 28, Acute Graft vs Host Disease at Day 100 and 4 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
granulocytes
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07372885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372885.